Reply To: PARP Inhibitors?
Hi Rick and Diana,
I’m forwarding your question to our consultants and will write on the forum with any helpful information.
In the meantime, I looked at clinicaltrials.gov and saw that there are are several clinical trials utilizing PARP inhibitors for carcinosarcoma.
1) Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer. ClinicalTrials.gov Identifier: NCT04034927 https://clinicaltrials.gov/ct2/show/NCT04034927?term=PARP+inhibitor&cond=carcinosarcoma&draw=2&rank=3
2) Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN), ClinicalTrials.gov Identifier: NCT03651206). This trial is not yet recruiting. https://clinicaltrials.gov/ct2/show/NCT03651206?term=PARP+inhibitor&cond=carcinosarcoma&draw=2&rank=2
I share this to let you know that researchers are looking to PARP inhibitors, among other therapies, to manage carcinosarcoma.
Best to you!
The GCS Project